Search research articles
Contact Us
Filters
Showing results (61-70 of 100) with videos related to
Page
of 10
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
September 3, 2022
Fracture Risk in Pediatric Patients With MEN2B
Iris Li, Iris R Hartley, Joanna Klubo-Gwiedzdzinska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor
John Glod, Fernanda I Arnaldez, Lori Wiener, et al.
Human Genetics
|
October 15, 2025
The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma
Chelsea Kotch, Alicia Gomes, Krista S Schatz, et al.
JAMA Dermatology
|
February 26, 2025
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial
Andrea M Gross, Olivia H Reid, Lauren A Baldwin, et al.
Journal of Pediatric Orthopedics
|
August 28, 2020
Are Some Randomized Clinical Trials Impossible?
Jonathan J Rios, B Stephens Richards, David A Stevenson, et al.
Neurology
|
August 17, 2016
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis
Shivani Ahlawat, Laura M Fayad, Muhammad Shayan Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Jaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Jaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Science Advances
|
April 30, 2019
RUNX represses <i>Pmp22</i> to drive neurofibromagenesis
Ashley Hall, Kwangmin Choi, Wei Liu, et al.
Sarcoma
|
August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 100) with videos related to
Sort By:
Page
of 10
The Journal of Clinical Endocrinology and Metabolism
|
September 3, 2022
Fracture Risk in Pediatric Patients With MEN2B
Iris Li, Iris R Hartley, Joanna Klubo-Gwiedzdzinska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor
John Glod, Fernanda I Arnaldez, Lori Wiener, et al.
Human Genetics
|
October 15, 2025
The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma
Chelsea Kotch, Alicia Gomes, Krista S Schatz, et al.
JAMA Dermatology
|
February 26, 2025
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial
Andrea M Gross, Olivia H Reid, Lauren A Baldwin, et al.
Journal of Pediatric Orthopedics
|
August 28, 2020
Are Some Randomized Clinical Trials Impossible?
Jonathan J Rios, B Stephens Richards, David A Stevenson, et al.
Neurology
|
August 17, 2016
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis
Shivani Ahlawat, Laura M Fayad, Muhammad Shayan Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Jaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Jaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Science Advances
|
April 30, 2019
RUNX represses <i>Pmp22</i> to drive neurofibromagenesis
Ashley Hall, Kwangmin Choi, Wei Liu, et al.
Sarcoma
|
August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Page
of 10